Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
Healthcare
$17.03 -0.42%
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
52W Low $10.44High $21.03
Volume 10.02M
Average 0.43M
Income Statement
Follow revenue through to earnings.
Revenue
$107.46M
FY 2025 · Annual
+66.9% YoYOperating Income
-$13.25M
FY 2025 · Annual
Net Income
$105.89M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.31M | 51.35M | 57.42M | 64.38M | 107.46M |
| Cost of Revenue | 193.66M | 63.39M | 40.62M | 37.64M | 5.52M |
| Gross Profit | (138.35M) | (12.05M) | 16.8M | 26.74M | 101.95M |
| Gross Margin | -250.1% | -23.5% | 29.3% | 41.5% | 94.9% |
| Research & Development | 201.55M | 70.07M | 46.34M | 38.05M | 37.41M |
| Selling, General & Admin | 99.3M | 67.07M | 70.45M | 69.17M | 73.65M |
| Operating Expenses | 119.44M | 79.91M | 72.84M | 73.69M | 115.2M |
| Depreciation & Amortization | 4.81M | 3.04M | 2M | 3.62M | 5.52M |
| EBITDA | (232.83M) | (76.08M) | (51.65M) | (38.45M) | 137.22M |
| EBITDA Margin | -420.9% | -148.2% | -89.9% | -59.7% | 127.7% |
| Operating Income | (257.78M) | (91.96M) | (56.04M) | (46.95M) | (13.25M) |
| Operating Margin | -466.1% | -179.1% | -97.6% | -72.9% | -12.3% |
| Interest Income | 1.11M | 8.55M | 9.12M | 4.88M | 0 |
| Interest Expense | 8.55M | 6.37M | 2.35M | 2.55M | 2.46M |
| Other Income / Expenses | (7.44M) | (858K) | 6.77M | 2.34M | 142.49M |
| Income Before Tax | (265.22M) | (92.82M) | (49.27M) | (44.61M) | 129.25M |
| Pre-Tax Margin | -479.5% | -180.8% | -85.8% | -69.3% | 120.3% |
| Income Tax Expense | (151K) | 9K | 5.92M | 11.8M | 23.35M |
| Net Income | (199.43M) | 872.13M | (55.19M) | (56.42M) | 105.9M |
| Net Margin | -360.6% | 1698.5% | -96.1% | -87.6% | 98.5% |
| EPS (Basic) | (2.87) | (1.26) | (1.00) | (1.15) | 2.10 |
| EPS (Diluted) | (2.87) | (1.26) | (1.00) | (1.15) | 2.06 |
| 69.46M | 73.59M | 55.3M | 48.85M | 50.32M | |
| 69.46M | 73.59M | 55.3M | 48.85M | 51.51M |
TBPH Earnings Waterfall · TTM
NASDAQ:TBPH · Revenue to Net Income
Key Ratios
EPS$2.20
Gross Margin77.0%
Net Margin83.1%
P/E Ratio3.8
P/S Ratio31.4
Analysis
$109.8M of revenue converted into $114.5M of net income for the selected period. Gross margin is 77.0% and net margin is 83.1%, showing how much revenue survives after costs and taxes. EPS is $2.20, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Sep 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| S-8 POS | S-8 POS filing | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 |
How much revenue does TBPH generate?
Theravance Biopharma, Inc. (TBPH) reported $107.46M of revenue in fiscal 2025.
Is TBPH profitable?
Theravance Biopharma, Inc. (TBPH) reported $105.89M of net income, with a net margin of 98.5%.
Continue the stock analysis
Jump to another research area for this company.